Monika Jampolska

Dr. Monika Jampolska

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
KKKatarzyna Kaczyńska
Katarzyna Kaczyńska
MJMonika Jampolska
Monika Jampolska
PWPiotr Wojciechowski
Piotr Wojciechowski
DSDorota Sulejczak
Dorota Sulejczak
KAKryspin Andrzejewski
Kryspin Andrzejewski
DZDominika Zając
Dominika Zając
Lactoferrin (LF) is a multifunctional iron-binding glycoprotein that exhibits a variety of properties, such as immunomodulatory, anti-inflammatory, antimicrobial, and anticancer, that can be used to treat numerous diseases. Lung diseases continue to be the leading cause of death and disability worldwide. Many of the therapies currently used to treat these diseases have limited efficacy or are associated with side effects. Therefore, there is a constant pursuit for new drugs and therapies, and LF is frequently considered a therapeutic agent and/or adjunct to drug-based therapies for the treatment of lung diseases. This article focuses on a review of the existing and most up-to-date literature on the contribution of the beneficial effects of LF on the treatment of lung diseases, including asthma, viral infections, cystic fibrosis, or lung cancer, among others. Although in vitro and in vivo studies indicate significant potency of LF in the treatment of the listed diseases, only in the case of respiratory tract infections do human studies seem to confirm them by demonstrating the effectiveness of LF in reducing episodes of illness and shortening the recovery period. For lung cancer, COVID-19 and sepsis, the reports are conflicting, and for other diseases, there is a paucity of human studies conclusively confirming the beneficial effects of LF.

Verified
Journal Article
Open access
PDF file
AWAgnieszka Wrzesień
Agnieszka Wrzesień
KAKryspin Andrzejewski
Kryspin Andrzejewski
MJMonika Jampolska
Monika Jampolska
KKKatarzyna Kaczyńska
Katarzyna Kaczyńska
Alzheimer’s disease (AD) is a neurodegenerative brain disease that is the most common cause of dementia among the elderly. In addition to dementia, which is the loss of cognitive function, including thinking, remembering, and reasoning, and behavioral abilities, AD patients also experience respiratory disturbances. The most common respiratory problems observed in AD patients are pneumonia, shortness of breath, respiratory muscle weakness, and obstructive sleep apnea (OSA). The latter is considered an outcome of Alzheimer’s disease and is suggested to be a causative factor. While this narrative review addresses the bidirectional relationship between obstructive sleep apnea and Alzheimer’s disease and reports on existing studies describing the most common respiratory disorders found in patients with Alzheimer’s disease, its main purpose is to review all currently available studies using animal models of Alzheimer’s disease to study respiratory impairments. These studies on animal models of AD are few in number but are crucial for establishing mechanisms, causation, implementing potential therapies for respiratory disorders, and ultimately applying these findings to clinical practice. This review summarizes what is already known in the context of research on respiratory disorders in animal models, while pointing out directions for future research.

Verified
Journal Article
Open access
PDF file
KKKatarzyna Kaczyńska
Katarzyna Kaczyńska
DZDominika Zając
Dominika Zając
PWPiotr Wojciechowski
Piotr Wojciechowski
MJMonika Jampolska
Monika Jampolska
Numerous regulatory peptides play a critical role in the pathogenesis of airway inflammation, airflow obstruction and hyperresponsiveness, which are hallmarks of asthma. Some of them exacerbate asthma symptoms, such as neuropeptide Y and tachykinins, while others have ameliorating properties, such as nociception, neurotensin or β-defensin 2. Interacting with peptide receptors located in the lungs or on immune cells opens up new therapeutic possibilities for the treatment of asthma, especially when it is resistant to available therapies. This article provides a concise review of the most important and current findings regarding the involvement of regulatory peptides in asthma pathology.

Verified
Journal Article
Open access
PDF file
DZDominika Zając
Dominika Zając
MJMonika Jampolska
Monika Jampolska
PWPiotr Wojciechowski
Piotr Wojciechowski
Molecular hydrogen is gaining increasing attention as an antioxidant, anti-inflammatory, and antiapoptotic agent. Once considered an inert gas, it reveals current therapeutic potential among others in inflammatory diseases, cancer, and sports medicine, among others. The present review aims to provide a consistent summary of the findings of the last twenty years on the use of molecular hydrogen in major respiratory diseases, including allergies, asthma, COPD, pulmonary fibrosis, lung injury of various origins, as well as cancer and infections of the respiratory tract. In addition, the basic mechanisms through which molecular hydrogen exercises its biological activity on the respiratory system are described.

1 October 2016 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
KKKatarzyna Kaczyńska
Katarzyna Kaczyńska
EKEwelina Kogut
Ewelina Kogut
DZDominika Zając
Dominika Zając
MJMonika Jampolska
Monika Jampolska
KAKryspin Andrzejewski
Kryspin Andrzejewski
PKPatrycja Kleczkowska
Patrycja Kleczkowska

26 July 2016 in Clinical and Experimental Pharmacology and Physiology
Verified
Journal Article
Closed access
PDF file
KKKatarzyna Kaczyńska
Katarzyna Kaczyńska
MJMonika Jampolska
Monika Jampolska
MSMałgorzata Szereda‐Przestaszewska
Małgorzata Szereda‐Przestaszewska